Make Informed Investment Decisions with Affordable Access to Experts
A Community Oncologist's View: Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approvalTicker(s): JAZZ, ABBV, RHHBY, AGIO
Name: Dr Salim Contractor
Institution: NY Oncology Hematology
- Medical oncologist within community practice (NY Oncology Hematology).
- Currently manages 20 patients with AML, 15 stage 4 RCC and 10 stage 1-3 RCC patients.
- Board Certified in Internal Medicine and Medical Oncology; fellowship trained (Oncology) at Mount Sinai.
Please describe your clinical practice; roughly how many patients with AML do you currently manage?Added By: c_admin
Have you prescribed Jazz Pharma's Vyxeos and/or Agios’ Idhifa/Tibsovo?Added By: c_admin
What are your thoughts on the FLT3 inhibitors (midostaurin and gilteritinib)? When do you test for FLT3 mutations and where do you see them best fitting into the treatment plan (maintenance? relapse?).Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.